EVLO - エベロ・バイオサイエンシズ （Evelo Biosciences Inc.）EVLOのニュース
Evelo Biosciences to Participate in the Cowen 43rd Annual Health Care Conference 2023/03/01 11:00:00 GlobeNewswire
CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered anti-inflammatory medicines acting on the small intestinal axis, SINTAX, today announced that Mark Plinio, J.D., Chief Commercial Officer will participate in a dermatology panel at the Cowen 43 rd Annual Health Care Conference on Tuesday, March 7, 2023 at 12:50 p.m. ET.
Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial 2023/02/27 11:00:00 GlobeNewswire
– Completed first blinded, placebo-controlled cohort in human volunteers with no safety or tolerability concerns –
Evelo Biosciences Inc PT Lowered to $2 at Morgan Stanley 2023/02/15 13:13:06 Investing.com
https://www.investing.com/news/pro/evelo-biosciences-inc-pt-lowered-to-2-at-morgan-stanley-432SI-3004105
Morning Volatile Movements: Phunware, Inc. (NASDAQ:PHUN 0.47%), Evelo Biosciences, Inc. (NASDAQ:EVLO -0.81%) 2023/02/13 18:19:30 Stock Equity
PHUN has seen its SMA50 which is now 3.95%. In looking the SMA 200 we see that the stock has seen a -20.98%. EVLO has seen its SMA50 which is … The post Morning Volatile Movements: Phunware, Inc. (NASDAQ:PHUN 0.47%), Evelo Biosciences, Inc. (NASDAQ:EVLO -0.81%) appeared first on Stocks Equity .
Evelo Biosciences Inc PT Lowered to $10 at BMO Capital 2023/02/06 17:47:02 Investing.com
https://www.investing.com/news/pro/evelo-biosciences-inc-pt-lowered-to-10-at-bmo-capital-432SI-2996349
Evelo Biosciences Inc PT Lowered to $10 at BMO Capital 2023/02/06 17:47:02 Investing.com
https://www.investing.com/news/pro/evelo-biosciences-inc-pt-lowered-to-10-at-bmo-capital-432SI-2996349
Evelo Biosciences'' Atopic Dermatitis Study Fails, Observes Unusually High Placebo Response Rates 2023/02/01 17:53:00 Benzinga
Evelo Biosciences Inc (NASDAQ: EVLO ) said it observed an unusually high placebo response rate in the first three cohorts of the EDP1815 Phase 2 atopic dermatitis study, resulting in a missed primary endpoint . The company said it is working through the data to understand the very high placebo rates observed in the trial, which occurred with greater prevalence in certain geographic regions. The trial''s fourth cohort, designed to test the … Full story available on Benzinga.com
Evelo Biosciences Collapses after Treatment Trial Fails 2023/02/01 17:40:33 TipRanks
Shares of biotech stock Evelo Biosciences (NASDAQ:EVLO) collapsed in today’s trading session. This can be attributed to the company’s eczema treatm…
Jefferies Downgrades Evelo Biosciences Inc to Underperform 2023/02/01 17:23:01 Investing.com
https://www.investing.com/news/pro/jefferies-downgrades-evelo-biosciences-inc-to-underperform-432SI-2993449
Quoin, F-star top healthcare gainers; Evelo, Taysha lead losers'' pack 2023/02/01 15:03:04 Seeking Alpha
Quoin Pharmaceuticals (QNRX) +49%. F-star Therapeutics (FSTX) +15%. Evelo Biosciences (EVLO) -24%. Taysha Gene Therapies (TSHA) -24%.
Evelo Biosciences GAAP EPS of -$0.28 in-line 2022/11/15 13:47:12 Seeking Alpha
Evelo Biosciences press release (EVLO): Q3 GAAP EPS of -$0.28 in-line.As of September 30, 2022, cash and cash equivalents were $69.1M, as compared to cash and cash equivalents of…
Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business Highlights 2022/11/14 22:27:00 GlobeNewswire
- Multiple Phase 2 readouts for EDP1815 in atopic dermatitis expected in 2023; data from first three cohorts expected in early 1Q 2023 and fourth cohort in 2Q 2023 -
Have you been able to find a good deal on Evelo Biosciences Inc.’s shares? 2022/09/19 15:48:00 US Post News
The share price of Evelo Biosciences Inc. (NASDAQ:EVLO) fell to $2.11 per share on Friday from $2.12. While Evelo Biosciences Inc. has underperformed by -0.47%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, EVLO fell by -71.14%, with highs and lows ranging from $12.74 to $1.42, […]
Evelo Biosciences (EVLO) Investor Presentation - Slideshow (NASDAQ:EVLO) 2022/09/16 22:15:36 Seeking Alpha
The following slide deck was published by Evelo Biosciences, Inc.
Do investors need to be concerned about Evelo Biosciences Inc. (EVLO)? 2022/09/05 15:40:00 US Post News
As of Friday, Evelo Biosciences Inc.’s (NASDAQ:EVLO) stock closed at $2.41, up from $2.29 the previous day. While Evelo Biosciences Inc. has overperformed by 5.47%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, EVLO fell by -78.60%, with highs and lows ranging from $12.74 to $1.42, […]